About us

Background


Dr. Eric van der Veer (CSO & founder) joined the Leiden University Medical Center (LUMC) as post-doc fellow in 2007. During his extensive research period (2007-2015) he focused mainly on RNA-based therapies. Due to his many successful publications, he was asked to become Assistant Professor at Leiden University. In October 2015, he came up with the idea to combine his knowledge on RNA with anti-viral therapies and the concept of Hybridize Therapeutics was born. In September 2019, Dr. Eric van der Veer decided to create a spin-off out of the LUMC and officially founded Hybridize Therapeutics. Currently, Hybridize Therapeutics is in the pre-clinical phase for our therapy against BK-virus and in the early pre-clinical phase for our therapy against SARS-CoV2 & JC-virus

 

Our Team


Eline Vrijland

CEO

Read Bio

Dr. Eric van der Veer

CSO & Founder

Read Bio

Alexander Mentink

Business Developer

Read Bio

Scientific co-founders

Prof. Dr. Anton Jan van Zonneveld

Laboratory Director (LUMC)

Read Bio

Jurriën Prins

Laboratory Supervisor (LUMC)

Read Bio

Strategic Advisory Board

Onno van der Stolpe

CEO Galapagos

Read Bio

Dr. John Maraganore

CEO Alnylam Pharmaceuticals

Read Bio

M.D. James Shannon

Ex-CMO GlaxoSmithKline

Read Bio

Dr. Dinko Valerio

Founder Crucell

Read Bio

Daniel de Boer

CEO ProQR

Read Bio

Dr. Andre Hoekema

CBO Galapagos

Read Bio

Scientific Advisory Board

Prof. Dr. Volker Nickeleit

University of North Carolina

Read Bio

Prof. Dr. Annemieke Aartsma-Rus

Professor Human Genetics, LUMC

Read Bio

Dr. Gerard Platenburg

CIO ProQR

Read Bio

Dr. Mariet Feltkamp

Associate Professor, LUMC

Read Bio

Network and industry exptertise of Hybridize Therapeutics


We leverage our extensive network of partners, that are leaders in their respective fields.

Patient associations

Health Care Collaborations

Regulatory Support

Investors

Our large clinical network and access to key opinion leaders includes different Nephrology research expert centers worldwide, among which the University of North Carolina at Chapel Hill School of Medicine, University of California in Los Angeles (UCLA), Hannover Medical Center in Germany and the Erasmus Medical Center (Rotterdam) and University of Groningen Medical Center (UMCG) in the Netherlands.